Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Abramson, Jeremy S  [Clear All Filters]
Journal Article
Ababneh HS, Abramson JS, P Johnson C, Patel CG. Assessing the Role of Radiotherapy in Patients with Refractory or Relapsed High-Grade B-Cell Lymphomas Treated with CAR T-Cell Therapy. Radiother Oncol. 2022.
Choe JH, Yu T, Abramson JS, Abou-El-Enein M. Cost-Effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv. 2023.
Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, et al. De novo CD5+ Diffuse Large B-cell Lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multi-center, rituximab treated cohort. Am J Hematol. 2016.
Abramson JS, Johnston PB, Kamdar M, Ibrahimi S, Izutsu K, Arnason JE, Glass B, Mutsaers PGNJ, Lunning M, Braverman J, et al. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Adv. 2022.
Abramson JS. High-dose chemotherapy and autologous stem cell transplantation for secondary central nervous system lymphoma: many are called, but few are chosen. Haematologica. 2013;98(5):662-4.
Karmali R, Abramson JS, Stephens DM, Barnes JA, Winter JN, Ma S, Gao J, Kaplan J, Petrich AM, Mi X, et al. Ibrutinib Maintenance Following Frontline Treatment in Patients with Mantle Cell Lymphoma. Blood Adv. 2023.
Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers PGNJ, Hernandez-Ilizaliturri FJ, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood. 2022.
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, et al. Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncol. 2024.